Instinct Bio Returns to Profit and Grows Revenue Nearly 10% in Yen Terms in First Half of Fiscal 2026

For the six months ended May 31, 2026, the Operating Group reported revenue of USD 1.14 million, up 4.7% in U.S. dollars and 9.8% in yen, and profit after tax of USD 90,251 versus a USD 206,817 loss a year earlier. Gross margin fell to 72.6% from 79.7%, cash was USD 25,565, and management said improving margins and cash position is a priority; the group had no bank borrowings but depends on receivable collections, related-party support and additional financing as needed. Overseas initiatives are targeted to become operational by end-2026, with revenue contribution expected from fiscal 2027, subject to agreements, approvals and partner performance.

Analysis

The headline earnings improvement is low quality until cash conversion and recurring costs are clearer. Profit benefited from lower listing-related expenses that are unlikely to recur, while gross-margin deterioration points to cost pressure that could offset modest operating growth. Yen growth exceeding reported-dollar growth also leaves results exposed to translation effects; imported inputs add potential currency and procurement volatility. The reduced largest-customer share improves resilience, but a still-material customer concentration means losing or repricing one account could overwhelm current profitability.

The more immediate risk is liquidity, not the stated growth initiatives: minimal cash alongside reliance on related-party collections, support and financing makes working-capital execution a key determinant of survival and dilution risk. The rise in related-party receivables/prepayments and related-party payables warrants scrutiny of aging, terms, recoverability and whether operating cash flow is sustainable. Historical operating-group results also do not establish the listed issuer’s full ongoing cost base.

Near term, the listing and results may draw attention, but the 1–3 month catalyst is evidence in the 6-K of collectible receivables and adequate funding. Over 6–18 months, U.S. and Indonesian plans could provide upside only after definitive agreements, approvals, partner execution and measurable revenue; until then, treat them as optionality, not a forecast. Potentially, established cosmetics and OEM suppliers benefit if execution stalls, but there is insufficient evidence to identify a direct public-market hedge. The contrarian point: lower customer concentration and positive earnings may look like a clean turnaround, yet weaker gross margin and fragile liquidity could dominate valuation. Falsify this caution with sustained margin stabilization, operating cash generation and a materially stronger cash position without growing related-party balances.

Key Decisions for Investors

• Do not underwrite the new-market initiatives as near-term revenue. Treat them as watch items until definitive agreements, regulatory progress and first customer sales are disclosed.
• Before taking directional exposure to Instinct Bio Technical Company Holdings, review the 6-K for related-party receivable aging and terms, director/related-party funding terms, subsequent cash movements, share count and ongoing public-company expenses. Missing details are central to the risk assessment.
• For existing exposure, set a review trigger around the next reported period: improving gross margin and operating cash flow without a build in related-party receivables would support the recovery case; further cash depletion, delayed collections or financing on dilutive terms would undermine it.
• No high-conviction long/short is justified from this release alone: market price, liquidity, float and financing terms are not provided, and those determine both valuation and whether a short is feasible.